Breast Cancer Research Trust NZ, gaining knowledge and saving lives

The CAMBRIA-2 trial

Purpose

The aim of CAMBRIA-2 is to prevent cancer from coming back for women diagnosed with this type of early breast cancer.

This is a hormone therapy clinical trial in oestrogen receptor positive and HER2 negative early breast cancer that has an intermediate to high, or high risk of recurrence.

Scientific Title

A Phase III, open-label, randomised study to assess the efficacy and safety of camizestrant (AZD9833, a next-generation, oral selective estrogen receptor degrader) versus standard endocrine therapy (aromatase inhibitor or tamoxifen) as adjuvant treatment for patients with ER positive/HER2 negative early breast cancer and an intermediate-high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence of disease.

Background

CAMBRIA-2 will test if giving a new hormone therapy called camizestrant from a class of drug called a ‘Selective Estrogen Receptor Degrader’ (SERD), is better at stopping cancer from returning, compared to the usual hormone therapies, such as letrozole, anastrozole, exemestane, or tamoxifen.

This research will also find out more about the side effects, safety and effectiveness of camizestrant.